FIELD: medicine.
SUBSTANCE: invention relates to a method of treating osteoarthritis in a subject, comprising administering to a subject a therapeutically effective amount of a low molecular weight cenolytic agent which selectively kills aging cells as compared to age-old cells. Aging cells are identified as p16-positive cells that are not cancer cells. Cenolytic agent is an MDM2 inhibitor and is administered directly into a joint affected by osteoarthritis. Also disclosed is a version of a method of treating osteoarthritis, a method of treating a non-proliferative associated with aging pulmonary disease or disorder in a subject and a method for increasing the stability of the atherosclerotic plaque.
EFFECT: invention enables treatment of diseases by selective killing of aging cells by administering a cenolytic agent.
54 cl, 72 dwg, 32 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TREATMENT OF EYE DISEASES SUCH AS MACULAR DEGENERATION, GLAUCOMA AND DIABETIC RETINOPATHY WITH MEDICATIONS THAT ELIMINATE AGING CELLS | 2018 |
|
RU2815482C2 |
| METHOD AND COMPOSITIONS FOR AGEING SUPPRESSION | 2010 |
|
RU2576512C2 |
| GENE TRANSITION MEDIATED BY LENTIVIRAL VECTOR AND METHOD FOR USING THE GENES | 2001 |
|
RU2288742C2 |
| COMPOSITIONS AND METHODS OF TREATING, PREVENTING AND REVERSING AGE-ASSOCIATED INFLAMMATION AND DISORDERS | 2020 |
|
RU2812903C2 |
| METHODS FOR TREATMENT USING SELECTIVE BCL-2 INHIBITORS | 2011 |
|
RU2593231C2 |
| PREDICTION OF RESPONSE TO ALVICIDIB BY ANALYSIS OF MITOCHONDRION PROFILE | 2016 |
|
RU2717829C2 |
| PHARMACEUTICAL COMPOSITION FOR INHIBITING NEURONAL APOPTOSIS OR NEURODEGENERATION | 2011 |
|
RU2586772C2 |
| COMBINATIONS OF LSD1 INHIBITORS FOR TREATING HAEMATOLOGICAL MALIGNANT DISEASES | 2017 |
|
RU2766259C2 |
| COMBINATION OF LSD1 INHIBITORS FOR TREATING HAEMATOLOGICAL MALIGNANT DISEASES | 2017 |
|
RU2816659C2 |
| METHODS AND COMPOSITIONS FOR AUTOIMMUNE AND INFLAMMATORY DISEASES TREATMENT | 2012 |
|
RU2639540C2 |
